International Vaccine Institute

This study tested a new vaccine called SchistoShield® in 120 healthy adults aged 20-59 in Burkina Faso and Madagascar. The goal was to check the vaccine's safety and how well it triggers the immune system. Participants received three doses of either the vaccine or a placebo over …